A Digital Twin of Empagliflozin Pharmacokinetics and Pharmacodynamics
Preprint
- 20 March 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives: Empagliflozin is an SGLT2 inhibitor prescribed for the management of type 2 diabetes mellitus, lowering blood glucose by increasing urinary glucose excretion (UGE) through inhibition of renal glucose reabsorption. PK/PD responses vary substantially across patient populations, complicating dose selection under altered organ function. Here, we developed a whole-body PBPK/PD digital twin integrating absorption, distribution, metabolism, and excretion with explicit modeling of renal glucose handling via the renal threshold for glucose. Methods: The model represents empagliflozin and its glucuronide metabolite, is implemented in SBML, and was calibrated and evaluated against curated PK/PD data from 27 clinical studies spanning healthy individuals, patients with type 2 diabetes, and cohorts with renal or hepatic impairment. Results: The model accurately captured observed clinical PK/PD data across all 27 studies, spanning a wide range of doses, dosing regimens, and patient populations. Good agreement between simulations and observations was obtained under normal and impaired renal and hepatic function, as well as under fasted and fed conditions, demonstrating the model's ability to reproduce empagliflozin disposition and pharmacodynamic response across clinically relevant scenarios. Conclusions: This SBML-based PBPK/PD digital twin provides quantitative insight into empagliflozin dose dependency and the impact of renal impairment, hepatic impairment, and food intake on PK/PD across clinically relevant populations. All model files, simulation scripts, and curated datasets are openly available in accordance with FAIR principles.Keywords
All Related Versions
This publication has 66 references indexed in Scilit:
- Mechanistic Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose ReabsorptionThe Journal of Clinical Pharmacology, 2024
- Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetesCPT: Pharmacometrics & Systems Pharmacology, 2023
- Combined experimental/computational aspects for the molecular interaction of empagliflozin with bovine serum albumin: Quantification and application to human plasmaLuminescence, 2023
- A model‐based meta analysis study of sodium glucose co‐transporter‐2 inhibitorsCPT: Pharmacometrics & Systems Pharmacology, 2023
- Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open‐label Randomized Single‐dose Two‐sequence, Two‐treatment, Two‐period Crossover StudyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2020
- Glucose transporters in the kidney in health and diseasePflügers Archiv - European Journal of Physiology, 2020
- Population Pharmacokinetic– Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes MellitusThe Journal of Clinical Pharmacology, 2017
- Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetesThe Journal of Clinical Pharmacology, 2013
- Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy SubjectsClinical Pharmacology in Drug Development, 2013
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973